title: Use of phenytoin in the prevention of motion sickness.
abstract: In a placebo-controlled double-blind crossover pilot study of acute Coriolis-induced motion sickness treatment/prevention in humans employing an anticonvulsant dose of phenytoin, a mean increase in tolerance to motion stress from 4.87 min (S.D. = 5.55) to 46.87 min (S.D. = 32.6) was obtained. This represents a greater than fourfold improvement in efficacy over any currently available single agent and is more than twice as effective as the scopolamine/dexadrine combination. There were none of the usual side effects of blurred vision, dizziness, dry mouth, or sedation.
authors: Air Force Institute of Technology, Wright-Patterson AFB, Dayton, OH 45433.
authors: W
authors: W
authors: Chelen
authors: M
authors: M
authors: Kabrisky
authors: C
authors: C
authors: Hatsell
authors: R
authors: R
authors: Morales
authors: E
authors: E
authors: Fix
authors: M
authors: M
authors: Scott
mesh_terms: D000284:Administration, Oral; D000328:Adult; D003312:Coriolis Force; D004311:Double-Blind Method; D004569:Electroencephalography; D006801:Humans; D008297:Male; D009041:Motion Sickness / Q000188:drug therapy* / Q000503:physiopathology; D010672:Phenytoin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D010672:Phenytoin